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FINE NEEDLE ASPIRATION OF THE THYROID
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SUMMARY ∑ Fine needle aspiration (FNA) of the thyroid has been utilized as a diagnostic method
for 40 years. The main purpose of thyroid FNA is to differentiate nodules that require surgery from
those that do not. The sensitivity of thyroid FNA ranges from 65% to 99%, and its specificity from
72% to 100%. Ultrasound-guided FNA of the thyroid is recommended, especially for sampling of a
small, deep nodule. One to four aspirations suffice in single nodular lesions measuring less than 3 cm
in diameter. Although the criteria used to establish specimen adequacy are somewhat controversial,
most institutions require the presence of follicular cells. FNA diagnosis of thyroid disease is a
clinicocytologic diagnosis, and correlation with clinical findings is mandatory for success. At our
institution, diagnostic FNA lesions are subdivided into the following general diagnostic categories:
benign, indeterminate, and malignant. Benign lesions include lesions with the diagnosis of benign
thyroid nodule, nodular goiter, and thyroiditis. Indeterminate lesions include cellular follicular le-
sion, follicular neoplasm and Hürthle cell neoplasm. Malignant neoplasms include papillary carci-
noma, high-grade follicular carcinoma, medullary carcinoma, anaplastic carcinoma, large cell lym-
phoma, and metastatic carcinoma. No clinical or laboratory test is sensitive and specific enough to
distinguish reliably whether a follicular neoplasm identified on FNA is benign or malignant. This
position may be changed with the development of molecular approaches to the diagnosis. CD44v6
and galectin-3 seem to be most promising tumor markers for thyroid malignancies of follicular epi-
thelial cell origin.
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Introduction
Fine needle aspiration (FNA) of the thyroid has been
utilized as a diagnostic method for 40 years. The method
was introduced by Söderström in 1952, has been exten-
sively used in Sweden and shown to be both dependable
and accurate1. However, the technique did not become
well accepted in the United States until the late 1970s2.
In Croatia, first experiences were reported in 1960s3,4. The
Swedish pioneers used air-dried smears usually stained
with May-Grünwald-Giemsa stain. In the United States,
alcohol-fixed material and either Papanicolaou or hema-
toxylin and eosin stains have been used. Prior to the use
of FNA, surgical excision of any remote suspicious lesion
was the norm. Since the introduction of this method, the
number of surgical procedures on the thyroid has been
reduced by 48% and the percentage of cancers in the sur-
gical material has risen from 11.5% to 43%5. Currently,
FNA of the thyroid has become the first-line diagnostic
technique in the evaluation of thyroid nodules, which is
used in conjunction with other modalities such as ultra-
sonography, radionuclide scanning, and biochemical and
antibody measurements as clinically indicated.
Clinically palpable thyroid nodules are exceedingly
common, with a number of different studies indicating an
annual incidence rate ranging from 4% to 8%6-13. Over-
all, there is a 10% life expectancy of developing a thyroid
nodule14. Therefore, thyroid nodules are one of the com-
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monest medical problems that physicians encounter. The
concern for both patients with thyroid nodules and their
physicians is the risk of malignancy. However, only a small
fraction of these lesions are caused by malignancy.
Although it appears that the incidence rate of thyroid
carcinoma may be slowly increasing, it is low, with annual
rates of only 25-40 per million population6,9,10,15. To-
gether, all the variants of thyroid carcinoma account for
only 1% of all new cancers7. Therefore, the vast majority
of palpable nodules are entirely benign, and only approxi-
mately 5% represent cancer16-18. The clinician’s funda-
mental goal is distinguishing the many benign from the
few malignant nodules. Ideally, surgical management
would be offered only to those thyroid nodule patients
harboring malignancies, and all other patients would be
managed more appropriately by conservative medical
treatment.
The main purpose of thyroid FNA is to differentiate
nodules that require surgery from those that do not. In
experienced hands, it is also diagnostic for certain thyroid
lesions, such as classic nodular goiter, Hashimoto’s thy-
roiditis, papillary carcinoma, high-grade follicular carci-
noma, medullary carcinoma, anaplastic carcinoma, large
cell lymphoma, and metastatic carcinoma.
However, FNA of the thyroid does not eliminate all
diagnostic operations. No test that serves a triage func-
tion is 100% effective, and the patient should be fully in-
formed about the risk/benefit ratio of the procedure. The
sensitivity of thyroid FNA ranges from 65% to 99%, and
its specificity from 72% to 100%12,19-22. The reported
false-negative rate ranges from 1% to 11%20,22-24. A false-
positive report in thyroid cytology is not of major concern
because, without this test, many more patients with soli-
tary, ‘cold’ nodules would require excision for diagnosis.
It is more important to maintain the lowest false-nega-
tive rate possible to ensure that few carcinomas will be
missed. The aim is to achieve a false-negative rate of less
than 2% and a false-positive rate of less than 3%22,24-30.
The incidence of false-negative diagnosis is difficult to
gauge because only approximately 10% of patients with
benign cytologic findings undergo surgery22. A false-
negative diagnosis is defined as a diagnosis of non-neo-
plastic lesion, which does not normally require surgery,
rendered on a malignant lesion. A false-positive cytologic
diagnosis is a diagnosis of neoplasm, which requires sur-
gery, rendered on a non-neoplastic lesion. The false-nega-
tive rate is computed as the number of false-negative di-
agnoses divided by the total number of FNAs in the se-
ries x100. A false-positive rate is computed as the num-
ber of false-positive diagnoses divided by the total num-
ber of FNAs in the series x10027.
Overall, FNA of the thyroid has resulted in a decrease
in the cost of medical care in thyroid disease. The inter-
pretation of the cytologic material from the thyroid is by
no means simple. Except in some obvious situations, the
identification of diagnostic cell patterns is difficult and
requires excellent material and a great deal of experience.
Targets of Aspiration Biopsy
The principal indication for FNA of the thyroid is a
solitary thyroid nodule. A classic multinodular gland is
rarely suspicious for carcinoma31. It is a long-standing
goiter with little or no progression in growth in a patient
without previous irradiation to the neck32. In multinodular
glands, the presence of a nodule that has grown rapidly,
become distinctly larger or dominant, or changed in tex-
ture or consistency warrants FNA33,34. Recent study shows
that the incidence of cancer is similar in those with clini-
cally apparent solitary and multiple nodules35. In those
with true solitary nodule confirmed at the operation, the
risk of cancer is the same as in those with multinodular
goiters36. FNA is also useful in patients with Hashimoto’s
thyroiditis because not only Hashimoto’s thyroiditis can
present as a solitary nodule but it can also coexist with
thyroid carcinoma or lymphoma.
FNA Technique
Thyroid FNA need not be restricted to specialized
centers; it can be performed effectively in a general hos-
pital setting, outpatient department, or free-standing
clinic. The individual who performs the aspiration must
have proper training in the method. Although consider-
able experience is required to obtain adequate material
with consistency, it is the intensity of experience rather
than the duration of FNA practice that is important25. It
is thought that examination of 30 to 40 FNAs annually
should be required to maintain interpretative profi-
ciency12,37-39.
Preparation of the Patient
The patient should be placed in supine position with
the neck extended; a pillow placed under the shoulders is
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helpful. Reviewing the procedure with the patient prior
to the aspiration usually appeases anxiety. The patient
should be advised not to swallow or talk during the pro-
cedure because movement of the gland during aspiration
may cause tissue tear and result in the formation of a he-
matoma.
Ultrasound-guided FNA of the thyroid is recom-
mended, especially for sampling of a small, deep nodule
or solid remnant of a cystic lesion40.
If FNA of the thyroid is performed without ultra-
sound guidance, the entire thyroid should be palpated to
determine the size and location of any abnormalities. The
area should be cleansed with alcohol. Local anesthesia is
not necessary. In patients who are very anxious topical
freezing anesthetics (or even an ice cube) may be used.
Aspiration Procedure
Use of a 25-gauge needle with disposable 10-cc sy-
ringe is recommended for obtaining thyroid samples41,42.
Drawing approximately 1-cc of air into the syringe prior
to the aspiration will facilitate expelling the specimen after
the procedure. During the puncture, the patient should
remain immobile. Aspiration must be performed compe-
tently and rapidly; otherwise, blood may enter the needle
and the syringe, making the material worthless. For cys-
tic lesions, a larger caliber, 23-gauge needle with 20-cc
syringe, may be used to evacuate as much of the fluid
content as possible. The slides for wet-fixation should
immediately be placed in alcohol or spray-fixed for Pa-
panicolaou or hematoxylin and eosin staining. Air-dried
slides are left unfixed until staining with May-Grünwald-
Giemsa stain.
The number of aspirations made in each patient de-
pends on the nature of the lesion. Generally speaking, one
to four aspirations suffice in single nodular lesions mea-
suring less than 3 cm in diameter. When the lesion is
larger, as many as six aspirations may be required. The
FNA procedure should be repeated for cases with inad-
equate yields, because repeating the aspiration provides an
adequate diagnostic sample in as much as 50% to 88% of
the initially unsatisfactory cases35,43,44.
Specimen Adequacy
The cytopathologist has a responsibility to recognize
when a specimen is inadequate for interpretation and to
communicate this to the clinician. Although the need for
obtaining adequate samples is unquestioned, issues regard-
ing the criteria used to establish specimen adequacy are
somewhat controversial. Most institutions require the
presence of follicular epithelial cells45. Everyone agrees
that any aspirate from a palpable nodule that contains
neither colloid nor epithelial cells is inadequate and should
be repeated45,46.
The cellularity of a specimen, however, is greatly in-
fluenced by the intrinsic nature of the lesion from which
the specimen was obtained. Many cases of benign colloid
goiter yield abundant colloid but few follicular cells. In
such cases, a diagnosis of ‘consistent with colloid goiter’
is acceptable, with the report containing a qualifier stat-
ing that the cytologic interpretation is limited by the pau-
city of follicular cells. Similarly, a cystic lesion that yields
numerous macrophages with scant or no follicular cells
may be reported as ‘consistent with benign thyroid cyst’,
with the qualifier indicating that the interpretation is lim-
ited by the paucity or lack of follicular cells. In case of
hemorrhagic cyst larger than 4 cm in diameter, the likeli-
hood of malignancy is higher, and repeat aspiration is
advised47.
If the criteria for FNA specimen adequacy are too lib-
eral, too many false-negative diagnoses will result; con-
versely, excessively narrow criteria will result in undue
patient anxiety, many repeat aspirations, or unnecessary
surgical excisions. If malignant cells, irrespective of the
number, are identified in an aspirate, it should automati-
cally be considered satisfactory. If too few malignant cells
are present for a definite diagnosis, a ‘suspicious’ diagno-
sis or repeat aspiration may be suggested46.
An acceptable rate of inadequate specimens is less than
15%46. No diagnosis should be rendered on inadequate or
unsatisfactory specimens.
Cytopathologic Reports
The written cytologic report should be clear, concise,
and clinically relevant. It is important to integrate clini-
cal information with cellular interpretation. An exact cy-
tologic diagnosis cannot be made only by observation of
the cells. The experience of the cytopathologist in weigh-
ing clinical information helps manage the examination of
the specimen, but the cells are still the crux of the matter.
The cytopathologist must be able to balance clinical bias
with microscopic examination. However, if the micro-
scopic material does not support the diagnosis, one should
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not make that diagnosis despite heavy clinical bias. Any
diagnosis made must be defensible to peer review.
Diagnostic Groups
FNA diagnosis of thyroid disease is a clinicocytologic
diagnosis, and correlation with clinical findings is man-
datory for success48. There is no consensus as to exact
format and style of reporting the results of FNA. In our
institution, we subdivide diagnostic FNA lesions into the
following general diagnostic categories: benign, indeter-
minate, and malignant (Table 1).
Table 1. Cytopathologic diagnoses
Benign lesions Benign thyroid nodule
Nodular goiter
Thyroiditis
Indeterminate lesions Cellular follicular lesion
Follicular neoplasm
Hürthle cell neoplasm







This group includes lesions with the diagnosis of be-
nign thyroid nodule, nodular goiter, and thyroiditis. When-
ever possible, a specific cytohistologic diagnosis should be
provided. For example, Hashimoto’s and DeQuervain’s
thyroiditis, colloid cyst and many nodular goiters can be
diagnosed with confidence and accuracy.
Lesions in this group can be managed conservatively.
If the nodules continue to enlarge, or fail to respond to
suppressive thyroxine therapy, then repeat aspiration or
surgical excision is indicated.
Indeterminate lesions
The definition of ‘indeterminate lesion’ is based on
the fact that what determines the need for surgery is the
diagnosis of a neoplastic versus non-neoplastic lesion.
These lesions pose the greatest diagnostic difficulty for
cytopathologist because there is substantial overlap in
cytologic features of benign non-neoplastic lesions and
well-differentiated follicular neoplasms (benign and ma-
lignant)49,50.
The three cytologic categories that are recognized are
cellular follicular lesion, follicular neoplasm and Hürthle
cell neoplasm.
Cellular follicular lesion is best described as ‘probably
neoplastic’. This group includes adenomatoid nodule,
nodule with Hürthle cell hyperplasia in Hashimoto’s thy-
roiditis, follicular adenoma, and Hürthle cell adenoma.
Hürthle cell carcinoma, a well-differentiated follicular
carcinoma, and some cases of the follicular variant of pap-
illary carcinoma are very rare exceptions but cannot be
excluded. FNAs show relatively abundant, slightly atypi-
cal, follicular (or Hürthle) cells and scant colloid. It should
be reported as ‘cellular follicular lesion’, with an added
comment outlining the differential diagnosis for each in-
dividual case.
When the diagnosis of ‘cellular follicular lesion’ is
made, and the patient is also judged to be at low risk,
conservative medical management with follow-up moni-
toring is advised. Factors that contribute to a low index
of suspicion of thyroid cancer include soft or cystic lesions,
‘hot’ nodules on radioisotope scan, and lesions that regress
during thyroxine suppression. High-risk factors for can-
cer include age (>60 yrs), male sex, large size (>4 cm),
rapidity of growth, rock hard texture of nodule, vocal cord
paralysis, previous exposure to radiation, family history of
medullary thyroid cancer, and growth during adequate
thyroxine suppression.
Follicular neoplasm is best described as ‘probably
malignant’. It includes follicular adenoma and follicular
carcinoma. Irregular microfollicles with nuclear overlap
and central, dense colloid, in association with cytologic
nuclear atypia, characterize follicular neoplasms42 (Fig. 1).
The determination of whether a follicular tumor is benign
or malignant is based on tissue architectural features of
capsular or vascular invasion, not cytomorphologic crite-
ria alone51-53. A cytologic diagnosis of follicular neoplasm
is an indication for surgical intervention, because this di-
agnosis implies that a well-differentiated carcinoma is not
excluded on the basis of cytologic examination.
Hürthle cell neoplasm includes both Hürthle cell ad-
enoma and Hürthle cell carcinoma. Their biologic behav-
ior and the rationale for considering them as a distinctive
clinicopathologic entity are debated53-56. However, the
frequency of malignant transformation and the biologic
aggressiveness of Hürthle cell tumors are superior to those
observed in other differentiated follicular tumors53,54.
They are indistinguishable from one another on the ba-
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sis of cytologic examination because the criteria for ma-
lignancy are based on the same architectural characteris-
tics as for follicular carcinomas. Aspirates are monomor-
phic, highly cellular with cells that show little cohesive-
ness, and have characteristic abundant, granular cytoplasm
with well-defined margins (Fig. 2). If FNA shows exclu-
sively Hürthle cells without background of thyroiditis, the
nodule should be surgically removed.
It is important to keep in mind that certain non-thy-
roid lesions in the neck, such as parathyroid adenoma and
carotid body paraganglioma, may show a follicular cyto-
logic pattern of FNA. If these are considered as diagnos-
tic possibilities, immunoperoxidase staining for thyroglo-
bulin and chromogranin may be helpful to resolve the
diagnostic problem.
Malignant neoplasms
This group includes any specimen in which an un-
equivocal diagnosis of malignancy can be made. More
common diagnoses are papillary carcinoma, high-grade
follicular carcinoma, medullary carcinoma, anaplastic car-
cinoma, large cell lymphoma, and metastatic carcinoma.
Papillary carcinomas are usually diagnosed readily by
FNA cytology. Characteristic findings include papillary
tissue fragments composed of enlarged cells with dense
cytoplasm, overlapping nuclei, finely granular ‘powdery’
Fig. 1. FNA of well-differentiated follicular carcinoma. Numerous
acini, slightly enlarged nuclei with mild anisonucleosis (May-
Grünwald-Giemsa stain, x200).
Fig. 2. FNA of Hürthle cell carcinoma. Monomorphic cells with
abundant, fine granular cytoplasm (May-Grünwald-Giemsa stain,
x200).
Fig. 3. FNA of papillary carcinoma. Enlarged cells with dense cy-
toplasm, finely granular ‘powdery’ chromatin, and intranuclear cy-
toplasmic inclusions (May-Grünwald-Giemsa stain, x400).
Fig. 4. FNA of high-grade follicular carcinoma. Syncytial pattern
with crowding, and overlapping of irregular nuclei (May-Grün-
wald-Giemsa stain, x200).
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chromatin, nucleoli, nuclear grooves, and intranuclear
cytoplasmic inclusions (Fig. 3). Psammoma bodies, dense
sticky colloid, and multinucleated giant cells may also be
present. When most of these criteria are met, the diag-
nosis poses little difficulty.
In high-grade follicular carcinomas, the nuclear con-
tour is less smooth, the chromatin tends to have an irregu-
lar pattern, and the large nucleoli are often prominent
(Fig. 4). Cells are arranged in irregular microfollicles with
crowding, and overlapping of nuclei.
Medullary carcinomas are unusual tumors that arise
from calcitonin-secreting C cells of the thyroid. The
cytomorphologic features are very characteristic. The tu-
mor cells occur singly or in loose monolayers. The cells
are round, oval, polygonal, triangular, or spindle, and have
abundant cytoplasm with red neurosecretory granules
(Fig. 5). Cells contain round or oval eccentric nuclei with
coarsely granular chromatin and small nucleoli.
The cytologic features of anaplastic carcinomas in
smears are highly specific and easy to recognize. Undif-
ferentiated, highly malignant cells show anisocytosis,
anisonucleosis, irregular, bizarre hyperchromatic nuclei,
numerous frequently pathologic mitoses, inflammation,
and necrosis (Fig. 6).
Primary lymphomas of the thyroid are of B-cell phe-
notype, usually arising in a setting of Hashimoto’s thy-
roiditis. The aspiration specimen lacks epithelial cell clus-
ters, and consists of monomorphic population of lym-
phoid cells that are dispersed or sometimes arranged into
lymphoid tissue fragments. Nuclei of the tumor cells are
uniform, and occupy most of the cytoplasm. Nuclear de-
tails vary according to the type of lymphoma.
The majority of thyroid metastases are produced by
contiguous spread of primary neoplasms of the pharynx,
larynx, and upper third of the esophagus. The thyroid is
subject to hematogenous disseminated disease in the ad-
vanced stages of carcinoma of the breast, lung, or kidney,
or melanoma, leukemia, and lymphoma. The differential
diagnosis of a primary thyroid tumor from a metastatic
tumor may become challenging in patients presenting
with new thyroid nodule and a history of malignancy57-
59. This is especially true if the neoplasm was in distant
past. Immunocytochemistry can be applied in FNA cy-
tology to help solve these dilemmas if the morphology is
not characteristic53.
For reliable diagnosis of malignancy multiple criteria
should be used. Specimens could be diagnosed as ‘suspi-
cious’ when cells show atypical features suggestive of but
not diagnostic for malignancy. These diagnoses are use-
ful, because they lead to surgical biopsy or excision of the
lesion.
Future Trends
In spite of the profusion of work available, only mar-
ginal success has been achieved in separating indetermi-
nate follicular lesions. Parameters used for these purpose
include morphologic features, such as cellular patterns,
morphometric criteria such as nuclear diameter, number
and margination of nucleoli, and flow cytometry, either
singly or in combination. The sensitivity of these results
varied from 40%60 to 75%61. No clinical or laboratory test
is sensitive and specific enough to distinguish reliably
Fig. 6. FNA of anaplastic carcinoma. Bizarre, pleomorphic cells with
irregular nuclei, prominent nucleoli and mitoses (May-Grünwald-
Giemsa stain, x400).
Fig. 5. FNA of medullary carcinoma. Round to oval cells with ec-
centric nuclei and abundant cytoplasm with red granules (May-
Grünwald-Giemsa stain, x1000).
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whether a follicular neoplasm identified on FNA is be-
nign or malignant. So, follicular lesions must be regarded
as suspicious and management is controversial. Age, clini-
cal features and discussion with patient will influence the
decision on surgery, however, many centers suggest sur-
gical excision of all indeterminate follicular lesions to
make definite histologic diagnosis. This position may be
changed with the development of molecular approaches
to diagnosis. Several molecules have been identified im-
munochemically and by reverse-transcriptase PCR as
potential targets for immunodiagnosis. Among these
molecules, CD44v6 and galectin-3 seem to be promising
markers for the detection of the presence of disregulated
cell growth and of thyrocytes that have undergone neo-
plastic transformation62-65. Galectin-3 is a valuable tumor
marker for thyroid malignancies of follicular epithelial cell
origin. This inexpensive and simple test, which combines
morphological and molecular evaluation, enhances the
accuracy of differential diagnosis between benign and
malignant thyroid neoplasms, improves clinical manage-
ment of thyroid lesions, and could contribute to the clas-
sification of as yet undefined thyroid lesions. The wider
application of this test method should help prevent un-
necessary surgical procedures and use of radiolabeled io-
dine compounds in the diagnosis of thyroid cancers.
Although there is no agreement on the optimum di-
agnostic strategy for the patient with nodular thyroid dis-
ease66, FNA thyroid cytology remains the most cost-ef-
fective, first-line diagnostic technique.
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Saæetak
ASPIRACIJSKA CITOLOGIJA ©TITNJA»E
N. Mateπa, N. DabeliÊ, I. Tabain i Z. KusiÊ
Aspiracijska citologija πtitnjaËe tankom iglom rabi se kao dijagnostiËka metoda veÊ 40 godina. Glavni cilj aspiracijske
citologije πtitnjaËe je razluËiti Ëvorove πtitnjaËe koji zahtijevaju kirurπko lijeËenje od onih Ëvorova kod kojih to nije potrebno.
Osjetljivost aspiracijske citologije πtitnjaËe varira izmeu 65% i 99%, a specifiËnost izmeu 72% i 100%. PreporuËa se provoditi
ju uz nadzor ultrazvuka, poglavito kod malih, dublje smjeπtenih Ëvorova. Kod Ëvorova promjera manjeg od 3 cm dovoljno je
izvrπiti jednu do Ëetiri aspiracije. Premda se kriteriji za prikladnost uzorka razlikuju od ustanove do ustanove, veÊina ih
zahtijeva prisutnost folikularnih stanica. Citoloπka dijagnoza bolesti πtitnjaËe zapravo je kliniËko-citoloπka dijagnoza, jer se
temelji na korelaciji citomorfoloπke slike i dostupnih kliniËkih podataka. U naπoj ustanovi dijagnostiËke citoloπke promjene
πtitnjaËe dijelimo u tri glavne kategorije: benigne, neodreenog znaËaja i maligne. Benigne promjene ukljuËuju dijagnoze kao
πto su benigni Ëvor πtitnjaËe, nodularna struma i tireoiditis. Promjene neodreenog znaËaja ukljuËuju celularnu folikularnu
promjenu, folikularni tumor i tumor Hürthleovih stanica. Maligne promjene ukljuËuju papilarni karcinom, slabo diferencirani
folikularni karcinom, medularni karcinom, anaplastiËni karcinom, limfom velikih stanica i metastatski karcinom. Niti jedan
kliniËki ni laboratorijski test nije dovoljno osjetljiv ni specifiËan da bi pouzdano razluËio maligne od benignih citoloπki
dijagnosticiranih folikularnih tumora πtitnjaËe. Ovakvo stanje moglo bi se izmijeniti  primjenom molekularne dijagnostike
tumora priËem se CD44v6 i galektin-3 nameÊu kao obeÊavajuÊi biljezi malignih stanica podrijetla folikularnih epitelnih
stanica.
KljuËne rijeËi: Bolesti πtitnjaËe, patologija; Neoplazme πtitnjaËe, patologija; Biopsija, igla; Citodijagnostika
